drugset / Trial / NCT01774773

A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)

NCT01774773

Phase 1 Completed 15 enrolled Eisai Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

E5501 (5 mg, 20 mg, and 40 mg) will be administered to healthy male adults in a single-center, randomized, open-label, cross-over manner. This study will consist of 2 phases including pre-randomization (before drug administration) and postrandomization (after drug administration).

Timeline

Start
2013-01
Primary completion
2013-07
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Avatrombopag Small molecule 5 mg
Subject Avatrombopag Small molecule 20 mg
Subject Avatrombopag Small molecule 40 mg

Indications

No indication recorded.